News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Yüksel Ürün: Cancer survivors face higher risk of cardiovascular disease
Yüksel Ürün/X
Feb 25, 2025, 09:40

Yüksel Ürün: Cancer survivors face higher risk of cardiovascular disease

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:

“Cancer survivors face 2-5x higher risk of cardiovascular disease.

Annual CV screening is a must! High-risk patients need further testing.

More research is needed to refine surveillance and prevention.”

Yüksel Ürün: Cancer survivors face higher risk of cardiovascular disease

More posts featuring Yüksel Ürün.

cancer Cardiovascular diseases OncoDaily Oncology Yüksel Ürün
Special Coverage
Blog
Mar 31, 2025, 14:02
Highlights from NCCN2025
Blog
Mar 31, 2025, 13:50
Raymond Chan: More MRFF funding for Flinders University on dementia and cancer survivorship
Blog
Mar 31, 2025, 13:37
Arun Shahi: Honored to be a guest of honor at the Maximizing Life Gala 2025
Blog
Mar 31, 2025, 13:24
Donal McLornan: Practical online tool to aid the transplant decision and discussion
Oncolibrary
Mar 31, 2025, 13:15
FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer
Insight
Mar 31, 2025, 13:03
Jennifer Lovick: Latest research from Technology in Cancer Research and Treatment's March round-up
Blog
Mar 31, 2025, 12:35
Zainul Aabideen: Spreading knowledge to save children with cancer
Blog
Mar 31, 2025, 12:34
MD Anderson Cancer Center - Physicians Share What They Love About Their Work for National Doctors' Day
Science
Mar 31, 2025, 12:30
Myeloma Paper of the Day, March 31st, suggested by Robert Orlowski
Blog
Mar 31, 2025, 12:28
Wafaa Rashed: Empowering the Next Generation of Genetics Policy Advocates
Oncolibrary
Mar 31, 2025, 12:26
New Paper Alert: Low-dose CT for lung cancer screening in a high-risk population (SUMMIT study)
Blog
Mar 31, 2025, 12:26
Drew Moghanaki: Selective SBRT can help patients with metastatic EGFR+ NSCLC get more MILEAGE out of every one of these drugs